CTOs on the Move


 
Ligand is a biopharmaceutical company focused on developing or acquiring technologies that help pharmaceutical companies discover and develop medicines. Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner ...
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.ligand.com
  • 3911 Sorrento Valley Boulevard
    San Diego, CA USA 92121
  • Phone: 858.550.7500

Executives

Name Title Contact Details

Similar Companies

Aptevo Therapeutics

Aptevo Therapeutics is a biotech company primarily focused on bringing novel oncology and hematology therapeutics to market. We leverage the innovative ADAPTIRâ„¢ platform technology, a unique approach to cancer immunotherapy, to improve outcomes for cancer patients.

BioEnterprise Corporation

BioEnterprise Corporation is a Cleveland, OH-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

BioElectron Technology Corporation

BioElectron is a platform biotechnology company, with expertise in the electron transfer (redox) chemical reactions that underpin oxidative stress and inflammation in all biological systems.

Matthew Gibbs

CipherBio@SVB: Search life science fundraising news and data to discover innovative companies backed by venture investors https://t.co/mmTCuwa0Mc

Hyasynth Bio

Natural molecules or derivatives make up more than half of the current drugs on the market with applications to nearly every disease known to humans. Salicylic acid, morphine, cannabinoids and insulin are a few examples. Our specialty is in producing these, and new targets, using a fast and scalable platform based on engineered microbes.